Heart Failure Clinical Trials

Alleviate HF

Principal Investigator: Anupam Basuray, MD

The Alleviate HF study will evaluate the ability of the Reveal LINQ™ Insertable Cardiac Monitor (ICM) to identify patients at high-risk of worsening heart failure. The trial will determine if early information provided by the LINQ devices help clinicians act before patients' conditions worsen. The LINQ device will alert clinicians if a patient is at high risk for a heart failure event, allowing time for a physician to adjust medications to enhance patient health.

You may be eligible to participate in this trial if you:

• Have a diagnosis of heart failure
• Have had a recent hospitalization or emergency room visit for worsening heart failure symptoms
• Do not currently have an implanted pacemaker or defibrillator device

AIM HIGHer Clinical Study Evaluation of CCM® Therapy for Heart Failure Patients with Higher EF

Principle Investigator: Katherine Dodd, DO

This study is a randomized, controlled study of 1500 patients designed to evaluate CCM® therapy safety and effectiveness in patients with symptomatic heart failure and an EF of 40 – 60%. Eligible patients will have the Optimizer® Smart Mini device implanted. Neither the physician nor the patient will be told if the device is turned on or off. Two-thirds of patients will be randomly assigned to therapy ON and one-third to therapy OFF. This approach allows for a scientific assessment of the therapy’s benefit. All subjects in the control group will be able to have the therapy turned on at 18 months.

WHAT IS CARDIAC CONTRACTILITY MODULATION? Cardiac contractility modulation is a therapy intended to treat patients with moderate to severe heart failure who continue to have symptoms despite optimal medical treatment and can benefit from an improved cardiac output.

Interested in learning more? Call the OhioHealth Research Institute at (614) 566-1250 or review the trial details and requirements at clinicaltrials.gov.